Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PfizerfiledCriticalPfizer
Priority to CU20070047ApriorityCriticalpatent/CU23648B7/en
Publication of CU20070047A7publicationCriticalpatent/CU20070047A7/en
Publication of CU23648B7publicationCriticalpatent/CU23648B7/en
Se proporciona un compuesto enantioméricamente puro de fórmula 1 ESPACIO PARA FÓRMULA así como procedimientos para su síntesis y uso. Los compuestos preferidos son potentes inhibidores de la proteína quinasa y son útiles en el tratamiento de trastornos del crecimiento celular anormal, tales como cánceres.An enantiomerically pure compound of formula 1 SPACE FOR FORMULA is provided as well as methods for its synthesis and use. Preferred compounds are potent protein kinase inhibitors and are useful in the treatment of abnormal cell growth disorders, such as cancers.
CU20070047A2007-02-232007-02-23
ENANTIOMERALLY PURE AMINOHETEROARILO COMPOUNDS AS QUINASE PROTEIN INHIBITORS
CU23648B7
(en)
DERIVATIVES OF N- (HETERO) ARIL-PIRROLIDINA DE PIRAZOL-4-IL-PIRROLO [2,3-D] PIRIMIDINAS AND PIRROL-3-IL-PIRROLO [2,3-D] PYRIMIDINS AS INHIBITORS OF THE JANUS KINASE.